COST CONSEQUENCES OF USING CLEVIDIPINE IN ACUTE HYPERTENSION FROM THE PERSPECTIVE OF A US HOSPITAL

被引：0
|
作者：
Gutierrez, M. [1 ]
Wild, S. [2 ]
Compton, A. [1 ]
Paine, E. [1 ]
Jensen, I. S. [3 ]
Shah, A. [4 ]
机构：
[1] Chiesi USA Inc, Cary, NC USA
[2] Chiesi USA Inc, Lindenhurst, IL USA
[3] Precis Hlth Econ & Outcomes Res, Boston, MA USA
[4] Precis HEOR, Chestnut Hill, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE125
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [31] COST ANALYSIS OF ADJUNCTIVE HYDROCORTISONE THERAPY FOR SEPTIC SHOCK FROM THE US PAYER PERSPECTIVE
    Oh, Mok
    Patanwala, Asad
    Alsaid, Nimer
    Almutairi, Abdulaali
    Abraham, Ivo
    Erstad, Brian
    CRITICAL CARE MEDICINE, 2019, 47
  • [32] Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in Patients with Acute Coronary Syndrome in PolandModelling Study from the Hospital Perspective
    Ewa Orlewska
    Andrzej Budaj
    Dariusz Tereszkowski-Kaminski
    PharmacoEconomics, 2003, 21 : 737 - 748
  • [33] Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective
    Murray, Brian
    Miles-Thomas, Jennifer
    Park, Amy J.
    Nguyen, Victor B.
    Tung, Amy
    Gillard, Patrick
    Lalla, Anjana
    Nitti, Victor W.
    Chermansky, Christopher J.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (02)
  • [34] COST EFFECTIVENESS OF MOMELOTINIB VS OTHER TREATMENTS FOR MYELOFIBROSIS FROM A US PAYER PERSPECTIVE
    Liu, T.
    Purser, M.
    Gong, C.
    Elsea, D.
    Niehoff, N.
    Dlotko, E.
    Migliaccio-Walle, K.
    Samyshkin, Y.
    VALUE IN HEALTH, 2024, 27 (06) : S112 - S112
  • [35] Cost minimalisation analysis of average acute hospital infections treatment with targocid (Teicoplanin) or vancomycine from service-provider perspective in Poland
    Kawalec, P.
    Lis, J.
    VALUE IN HEALTH, 2006, 9 (06) : A302 - A302
  • [36] INVASIVE FUNGAL INFECTION (IFI) IN PATIENTS WITH ACUTE MYELOGENOUS LEUKAEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)-TREATMENT COST FROM HOSPITAL PERSPECTIVE
    Berger, K.
    Cornely, O. A.
    Hoppe-Tichy, T.
    Kiehl, M.
    Knoth, H.
    Rieger, C.
    Thalheimer, M.
    Schuler, U.
    Ullmann, A. J.
    Ostermann, H.
    VALUE IN HEALTH, 2008, 11 (06) : A478 - A479
  • [37] Cost Determinants of Percutaneous and Surgical Interventions for Treatment of Intermittent Claudication from the Perspective of the Hospital
    Bertrand Janne d’Othée
    Michael F. Morris
    Richard J. Powell
    Michael A. Bettmann
    CardioVascular and Interventional Radiology, 2008, 31 : 56 - 65
  • [38] Evaluation of drug cost savings related to clinical trials from the perspective of a university hospital
    Perrier, Quentin
    Minoves, Melanie
    Cerana, Sophie
    Reymond, Fabienne
    Ducki, Camille
    Decaens, Thomas
    Lehmann, Audrey
    Bedouch, Pierrick
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (06) : 520 - 525
  • [39] Cost determinants of percutaneous and surgical interventions for treatment of intermittent claudication from the perspective of the hospital
    d'Othee, Bertrand Janne
    Morris, Michael F.
    Powell, Richard J.
    Bettmann, Michael A.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2008, 31 (01) : 56 - 65
  • [40] Reprocessing Cost Analysis of Specimens Rejected in Laboratory: Results from the Perspective of the Costs to the Hospital
    Bozdemir, Enver
    Kurutkan, Mehmet Nurullah
    Terzi, Melek
    CLINICAL AND EXPERIMENTAL HEALTH SCIENCES, 2022, 12 (01): : 67 - 74
12345